Most Read Articles
Pearl Toh, 4 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Physical therapy referral improves outcomes of patients with sciatica

17 Oct 2020

Referral of patients with recent-onset sciatica from primary care to physical therapy improves disability and other outcomes compared with usual care, a study has shown.

A total of 220 adults aged 18–60 years with sciatica of <90 days’ duration who were making an initial primary care consultation were randomized to early physical therapy (EPT; n=110) or usual care (n=110). The usual care group received one education session, while the EPT group received one education session and was then referred for 4 weeks of physical therapy, including exercise and manual therapy.

All participants received imaging and medication at the discretion of the primary care provider prior to enrolment. The Oswestry Disability Index (OSW) score after 6 months was the primary outcome. Secondary outcomes included pain intensity, patient-reported treatment success, healthcare use, and missed workdays.

The EPT group showed greater improvement from baseline to 6 months for the primary outcome (relative difference, –5.4 points, 95 percent confidence interval [CI], –9.4 to –1.3; p=0.009). After 4 weeks, EPT resulted in more favourable OSW and secondary outcomes. After 1 year, between-group differences still favoured EPT for the OSW (relative difference, –4.8 points, 95 percent CI, –8.9 to –0.7) and back pain intensity (relative difference, –1.0 points, 95 percent CI, –1.6 to –0.4).

Patients in the EPT group were more likely to self-report treatment success after 1 year than those in the usual care group (45.2 percent vs 27.6 percent; relative risk, 1.6, 95 percent CI, 1.1–2.4). No significant between-group differences were seen in healthcare use or missed workdays.

The study was limited by the unblinded patients and providers. In addition, specific physical therapy interventions responsible for effects could not be determined.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.